Myxoid liposarcoma (MLPS) has been reported to be more radiosensitive compared with other soft tissue sarcomas. The main objective of the study is to assess the efficacy of hypofractionated radiotherapy in preoperative setting in patients with locally advanced primary MLPS.
Single-arm prospective clinical trial enrolls MLPS patients for preoperative 5x5 Gy RT with 6-8 weeks gap between RT end and surgery. The endpoints of the study are the rate of early wound healing complications and 5- year local control rate.
Since the study opening in May 2015 19 patients (pts) have been included: 16 finished the whole planned protocol treatment; 3 pts are awaiting surgery now. All but one of the patients had the tumors located on the lower limb. The median size of the tumor was 14 cm (range 5-20 cm), 40% of the patients had high grade tumors as assessed by FNCLCC and 40% of the patient had more than 5% od round cell component. Early RT tolerance was good. EORTC grade 1 radiation dermatitis developed in 10 pts and grade 3 in 1 patient. Postoperative wound complications occurred in 3 pts as wound dehiscence and prolonged wound healing. R0 margins were achieved in all but one patient 1 patient which had an R1 resection margin. None of the patient had local recurrence.
Preoperative hypofractionated RT with a long gap between the radiotherapy and surgery is a feasible method of the management of MLPS providing a good local control and low rates of treatment toxicity.
Clinical trial identification
Legal entity responsible for the study
Hanna Koseła-Paterczyk, Piotr Rutkowski.
Has not received any funding.
P.L. Rutkowski: Honoraria: Bristol-Myers Squibb, Roche, Novartis, Merck, Sharp & Dohme, GlaxoSmithKline; Paid consulting role: Bristol-Myers Squibb, Roche, Merck, Sharp & Dohme, Blueprint Medicines, Amgen; Speakers’ bureau: Novartis, Pfizer, Merck, Sharp & Dohme; Institutional research funding: Bristol-Myers Squibb, Novartis; Travel expenses: Novartis, Orphan Drugs. All other authors have declared no conflicts of interest.